Nilotinib is an orally bio-available aminopyrimidine-derivative Bcr-Abl tyrosine kinase inhibitor (IC50 < 30 nM) with anti-neoplastic activity.
Product Details
| Alternative Name: | AMN107, Nilotinibum, 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide |
| |
| Formula: | C28H22F3N7O |
| |
| MW: | 529.5 |
| |
| CAS: | 641571-10-0 |
| |
| Purity: | ≥99% (HPLC) |
| |
| Identity: | Determined by EM-MS, NMR |
| |
| Appearance: | Beige powder. |
| |
| Solubility: | Soluble in DMSO (12 mg/ml) or ethanol (1mg/ml). |
| |
| Shipping: | Ambient Temperature |
| |
| Short Term Storage: | +4°C |
| |
| Long Term Storage: | -20°C |
| |
| Scientific Background: | BCR-ABL, a common molecular defect in adult acute lymphoblastic leukemia, is a valuable tumor marker whose detection influences prognosis and clinical management decisions. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
